Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ATIC | P31939 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707241 | 0.78 | IMPDH2 (0.50) | IMPDH2IMPDH1XDHSLC22A12RIPK1 | |
| SCHEMBL16636645 | 0.78 | IMPDH2 (0.50) | IMPDH2IMPDH1XDHSLC22A12RIPK1 | |
| SCHEMBL988243 | 0.78 | IMPDH2 (0.50) | IMPDH2IMPDH1XDHSLC22A12RIPK1 | |
| SCHEMBL2537652 | 0.76 | AHR (0.50) | RIPK1TNFGPR84SLC6A2SLC6A4 | |
| SCHEMBL29337991 | 0.75 | IKBKB (0.44) | IMPDH2IMPDH1IKBKBCHUKSLC6A2 | |
| SCHEMBL28597933 | 0.73 | XDH (0.50) | IMPDH2IMPDH1XDHSLC22A12RIPK1 | |
| SCHEMBL12585067 | 0.73 | XDH (0.64) | IMPDH2IMPDH1XDHSLC22A12IKBKB | |
| SCHEMBL794596 | 0.72 | TNF (0.44) | RIPK1IKBKBCHUKTNFGPR84 | |
| SCHEMBL31357932 | 0.72 | AHR (0.47) | IMPDH2IMPDH1XDHSLC22A12RIPK1 | |
| SCHEMBL1420429 | 0.72 | AHR (0.47) | IMPDH2IMPDH1XDHSLC22A12RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-11117887-B2 | Aryl substituted pyrimidines for use in influenza virus infection | Janssen Sciences Ireland Unlimited Company (IE) | 2021-09-14 | — | — | US | disclosed |
| EP-3405466-B1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-11-18 | — | — | EP | disclosed |
| CN-106573920-B | Indoles for use in influenza virus infection | 爱尔兰詹森科学公司 | 2020-11-10 | — | — | CN | disclosed |
| US-20200231577-A1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE INFLUENZA VIRUS INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2020-07-23 | — | — | US | disclosed |
| US-10611755-B2 | Aryl substituted pyrimidines for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2020-04-07 | — | — | US | disclosed |
| US-10597390-B2 | Indoles for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2020-03-24 | — | — | US | disclosed |
| US-20190047989-A1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2019-02-14 | — | — | US | disclosed |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| WO-2017125506-A1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-27 | — | — | WO | disclosed |
| WO-2016020526-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UC (IE) | 2016-02-11 | — | — | WO | disclosed |
| US-9000175-B2 | Bicyclic GPR119 modulators | LUPIN LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611755-B2 | Aryl substituted pyrimidines for use in influenza virus infection | HPRT1, TYMP, PNP | IMPDH2 13/4885IMPDH1 5/4885XDH 16/4885 |
| US-11117887-B2 | Aryl substituted pyrimidines for use in influenza virus infection | HPRT1, TYMP, PNP | IMPDH2 13/4885IMPDH1 5/4885XDH 16/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | IMPDH2 1775/4885IMPDH1 1757/4885XDH 684/4885 |
| US-20190047989-A1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | HPRT1, TYMP, PNP | IMPDH2 13/4885IMPDH1 5/4885XDH 16/4885 |
| US-10597390-B2 | Indoles for use in influenza virus infection | IDO1, IDO2, INMT | IMPDH2 28/4885IMPDH1 17/4885XDH 175/4885 |
| US-20200231577-A1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE INFLUENZA VIRUS INFECTION | HPRT1, TYMP, UMPS | IMPDH2 26/4885IMPDH1 7/4885XDH 21/4885 |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | IDO1, IDO2, INMT | IMPDH2 28/4885IMPDH1 17/4885XDH 175/4885 |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | IMPDH2 3334/4885IMPDH1 3332/4885XDH 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.